Clinical Trial: Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612137) titled 'Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors' on May 21.

Brief Summary: To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Solid Tumor

Intervention: DRUG: IBI3005

Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R & D code: IBI3005)

DRUG: Sintilimab

Anti-PD-1 Monoclonal Antibody

DRUG: Bevac...